United States: Greg Vogel On "Government Funding For Pharmaceutical Research And Development"

Last Updated: November 28 2017
Article by Greg Vogel

All companies have to make difficult choices prioritizing objectives. In addition to other factors, pharmaceutical companies must also consider the potential of any given clinical development plan years before success or failure can be determined. Bringing a product to market is costly, not only in terms of direct research and development costs, but also the opportunity costs of potential products that get deprioritized in a company's cost-benefit analyses. These cost-benefit analyses have real world consequences - it is not an understatement to say that in the pharmaceutical field, a company's decisions, successes, and failures directly affect the lives of its end users.

U.S. government contracts can nudge companies toward developing drugs, countermeasures, and related diagnostics deemed essential to U.S. public health and safety and can alter a company's priorities. For example, programs managed by the Department of Health and Human Services (HHS) in recent years have supported research for vaccines and therapeutics in the fields of influenza, anthrax, Ebola, and Zika.1 In the last several years, HHS awarded an $8.9 million contract to support a new Zika diagnostic test,2 a $43 million contract for development of a Zika vaccine (with options up to $130 million if development advances),3 and a $198.8 million contract to support development and licensure of an anthrax vaccine.4

Absent government funding, companies might focus only on treatments for more commonly-occurring conditions, even if they are not life-threatening. For example, innovation in the area of influenza vaccines likely would not be considered a "blockbuster," and yet it remains important due to the potentially devastating consequences of an outbreak. Government funding, however, comes with numerous terms and conditions intended to protect taxpayer money and implement socioeconomic goals. Companies following standard accounting and subcontracting practices will be required to implement additional procedural and reporting safeguards. The following is a high-level description of just a few of these requirements to give an impression of the strings that attach to government contracts.

Accounting for Costs

Due to the nature of the work, research and development contracts are likely to be funded by government reimbursement of costs incurred rather than payment on a fixed-price basis. The U.S. government's Cost Accounting Standards (CAS)5 and the Federal Acquisition Regulation (FAR) cost principles6 impose specific requirements to the calculation of costs incurred in the performance of a contract, and a company's compliance is subject to rigorous review and audit by the Defense Contract Audit Agency.7 Always looming in the background is the healthy fear of termination for default, suspension or debarment, or even a False Claims Act (FCA)8 allegation for a failure to comply with cost accounting requirements.9

To comply with cost accounting requirements, a company must establish appropriate methods for calculating direct costs. This includes proper management of a timekeeping system that accurately records labor hours, and procurement processes that not only capture subcontractor and vendor costs, but also flow down numerous FAR and prime contract requirements to lower tiers. Implementation can be difficult, especially where processes are already in place for "civilian" purposes to minimize timekeeping burdens and streamline purchasing. A failure to implement appropriate systems can lead to incomplete reimbursement and wasted costs on the part of the company, not to mention the risk of suspension, debarment, and an FCA claim, as noted above.

In addition, CAS-compliant companies will normally be required to submit a Disclosure Statement (DS-1), detailing its methods for calculating indirect costs.10 The DS-1 must be revised whenever a company's methods of calculating overhead, fringe benefits, and general and administrative costs change. Generally, during contract negotiations, the company and federal agency providing the funding will agree on provisional indirect rates to be charged to the contract, including allowable profit. To comply with the FAR, a company will be required annually to submit an Incurred Cost Submission (ICS), calculating the actual indirect costs incurred in the previous year, and adjusting those actual rates up or down from the previous years' invoicing of the provisional rates through a true-up process. The actual rates in the ICS normally become the provisional rate for the next year, and the cycle continues through contract close-out. For many companies, sharing indirect cost data so openly with a customer can be daunting, but the spending of public funds warrants such transparency.

Subcontracting Requirements

As noted above, a company may have a perfectly good subcontractor or vendor management system in place for "civilian" purposes. Upon entering into a government contract, a company accedes to a critical extra step in its normal process: agency contracting officer approval of subcontracts.11 It is possible to avoid subcontract-by-subcontract approval requirements by establishing an "approved purchasing system," but the process of obtaining approval can be onerous and is therefore generally reserved for companies performing government contracts as a large proportion of their business.12 Awaiting contracting officer approval can delay urgent purchases, and must be accounted for in program timelines.

In addition, the government uses contracts to encourage contractors to engage particular entities, such as small, disadvantaged, woman-owned, minority-owned, and service-disabled veteran-owned businesses as subcontractors. Contractors must agree to a small business subcontracting plan that commits to achieving the agency's subcontracting goals, measured as a percentage of the dollar value of the total dollars spent under the contract.13

Even if a company already has a company-wide small business subcontracting plan as an element of its procurement program, it still may be required to implement small business subcontracting plans for each individual government contract, and to use good faith efforts to engage such suppliers in support of the contract. Meeting the goals of contract-by-contract small business subcontracting plans can be especially difficult for pharmaceutical companies, because they often subcontract to contract manufacturing organizations and contract research organizations for a large proportion of research and development programs, and these are often classified as "other than small" businesses. Indeed, there are many reasons, such as trustworthiness, volume discounts, and the complexity of technology transfers between the entities, that can limit the incentive to seek out new and untested businesses in these areas. Therefore, good faith efforts often require companies to look to other aspects of contractor performance, such as scientific writing and statistical analysis, to try and fulfill these small business requirements. Notably, under new rules, a prime contractor may include lower-tiered small business subcontractors toward the prime contractor's goals in some cases, even if the first-tiered subcontractor is not a small business. Contractors are required to report twice a year on its small business subcontracting efforts in relation to the goals stated in their plans.14

Additional Reporting Requirements

Subject Invention Reporting

The Bayh-Dole Act15 (supplemented by Executive Orders 1259116 and 1261817) permit companies to keep title to certain inventions arising out of government contracts ("subject inventions"), although the government may retain title in certain situations, such as where the inventing company is not located in the United States or is subject to the control of a foreign government. In any event, the government retains a government purpose license as well as "march in" rights in subject inventions that apply when a company either fails to, or decides not to, commercialize a subject invention. In the pharmaceutical context, subject inventions could include a new manufacturing process, new drug administration methods, and other patentable or protectable inventions or discoveries arising out of government-funded research.

In order to keep title to subject inventions, contractors must meet the reporting requirements laid out in FAR Part 27 and FAR Clause 52.227-11.18 These require the company to report inventions to the agency contracting officer within two months of the invention being disclosed internally to the person responsible for patent matters within the company. The company then has two years to elect to retain title, and another year to file a provisional or non-provisional patent application. A company must be familiar with these reporting requirements, because a failure to timely report could lead to the government acquiring title. Even worse, should the government attain title, the government may also license rights to the development and commercialization of a subject invention to a competitor. While rare, the potential consequences could have a tremendous negative financial and reputational impact on a company and must be taken seriously.

Earned Value Management Reporting

The government, and especially HHS, has moved recently to requiring research and development contractors to comply with "Earned Value Management System" requirements. EVMS is a performance management tool that requires a contractor to divide projects into measurable cost and progress increments and to provide this costs-versus-progress data to the government monthly in a specific format.19 The level of detail required is dependent on the value of the contract. Here, too, a contractor may have a perfectly good "civilian" project management system in place, and yet will be required to add another layer of data consolidation and reporting in order to comply with the contract, including potentially purchasing particular software or hiring an expert.


Government funding is available to encourage research and development of pharmaceutical products that could contribute to the public health, even though the costs associated with development would normally be prohibitive or development of such a product would otherwise be deprioritized. A company seeking to enter this sphere should review requests for proposals carefully to understand the terms and conditions that will apply to a resulting contract, and the costs of compliance - and the risks of compliance failure - that accompany government funding must be added to a company's assessment of priorities. The foregoing is only a small sample of the compliance requirements that will apply to a company that takes the leap and becomes a government contractor.20 Once appropriate compliance systems are in place, government funding sources can help pharmaceutical companies conduct research and development in areas that may otherwise be put on the backburner for want of funds.

Originally published by ABA Health Law September 2017


1 In 2006, HHS established The Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) to "coordinate[] Federal efforts to enhance Biological, Chemical, Radiological and Nuclear threats and Emerging Infectious Diseases (EID) preparedness from a medical countermeasure perspective." PHEMCE continues to address the medical countermeasures needed to protect against high priority threats that have the potential to seriously threaten national health security. Some of these high priority threats include anthrax, typhus, influenza, and Ebola. See https://www.phe.gov/Preparedness/mcm/phemce/Pages/default.aspx.

2 https://www.phe.gov/about/barda/Pages/NewsReleases.aspx.

3 https://wayback.archive-it.org/3926/20170127192443/https://www.hhs.gov/about/news/2016/09/26/barda-awards-funding-speed-development-zika-vaccine.html.

4 https://wayback.archive-it.org/3926/20170129092815/https://www.hhs.gov/about/news/2016/09/30/hhs-supports-next-generation-anthrax-vaccine-advanced-development.html.

5 48 C.F.R. Part 99.

6 48 C.F.R. Part 31.

7 DCAA includes links to guidance and relevant regulations online at http://www.dcaa.mil/Home/Guidance (last accessed July 18, 2017).

8 31 U.S.C. §§ 3729-3733.

9 The government could allege that such a compliance failure, and the resulting flawed invoices submitted, constitute false statements under the False Claims Act.

10 48 C.F.R. Clause 9903.202-1. A Disclosure Statement is a written description of a contractor's cost accounting practices and procedures. The submission of a new or revised Disclosure Statement is not required for any non-CAS-covered contract or from any small business concern.

11 48 C.F.R. Subpart 44.2.

12 48 C.F.R. Subpart 44.3. A Contractors' Purchasing System Review is performed by an appointed Administrative Contracting Officer (ACO), and it is not specific to any individual contract but rather the contractor itself. The ACO will review a contractor's use of competition, evaluation of subcontractor responsibility, compliance with Cost Accounting Standards, and use of small business subcontractors, among other things.

13 48 C.F.R. Subpart 19.7.

14 48 C.F.R. Clause 52.219-9.

15 35 U.S.C. Chapter 18. Public Law 96-517, https://www.gpo.gov/fdsys/pkg/STATUTE-94/pdf/STATUTE-94-Pg3015.pdf (last accessed July 18, 2017).

16 https://www.archives.gov/federal-register/codification/executive-order/12591.html (last accessed July 18, 2017).

17 http://www.presidency.ucsb.edu/ws/index.php?pid=33850 (last accessed July 18, 2017).

18 48 C.F.R. Part 27 and 48 C.F.R. Clause 52.227-11.

19 48 C.F.R. Subpart 34.2.

20 In 1965, President Lyndon Johnson signed Executive Order 11246 granting supervision of federal contract compliance to the Secretary of Labor, and creating the department's first Office of Federal Contract Compliance. The Executive Order prohibits federal contractors and federally-assisted construction contractors and subcontractors from discriminating in employment decisions based on race, color, religion, sex, sexual orientation, gender identity, or national origin. It also requires the Government to take affirmative action to make sure equal opportunity is given to employees in all aspects of their employment. Additionally, the Executive Order prohibits federal contractors from taking adverse employment actions against applicants and employees. Also, more recently President Obama issued Executive Orders that imposed additional requirements on federal contractors, such as Executive Order 13496, which requires federal contractors and subcontractors to notify employees about their rights under the National Labor Relations Act.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions